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Background: Tuberculosis is a major infectious disease and functional studies have provided evidence that both the
chemokine MIP-1α and its receptor CCR5 play a role in susceptibility to TB. Thus by measuring copy number variation
of CCL3L1, one of the genes that encode MIP-1α, and genotyping a functional promoter polymorphism -2459A > G in
CCR5 (rs1799987) we investigate the influence of MIP-1α and CCR5, independently and combined, in susceptibility to
clinically active TB in three populations, a Peruvian population (n = 1132), a !Xhosa population (n = 605) and a South
African Coloured population (n = 221). The three populations include patients with clinically diagnosed pulmonary TB,
as well as other, less prevalent forms of extrapulmonary TB.
Methods and results: Copy number of CCL3L1 was measured using the paralogue ratio test and exhibited ranges
between 0–6 copies per diploid genome (pdg) in Peru, between 0–12 pdg in !Xhosa samples and between 0–10 pdg
in South African Coloured samples. The CCR5 promoter polymorphism was observed to differ significantly in allele
frequency between populations (*A; Peru f = 0.67, !Xhosa f = 0.38, Coloured f = 0.48).
Conclusions: The case–control association studies performed however find, surprisingly, no evidence for an influence
of variation in genes coding for MIP-1α or CCR5 individually or together in susceptibility to clinically active TB in these
populations.
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Tuberculosis (TB), caused by the pathogen Mycobacterium
tuberculosis, is a leading cause of global mortality and mor-
bidity. The World Health Organisation estimates that one
third of the world’s population is infected with TB, with an
estimated 1.7 million deaths from TB in 2009.
A good protective immune response againstM. tuberculosis
requires the formation of discrete granulomatous lesions
to contain the mycobacteria, and a complex interaction
between activated T cells, macrophages and polymorpho-
nuclear leucocytes [1]. The granuloma creates a micro-
environment where infected macrophages, dendritic cells
and different T-cell populations exist in close proximity
and limit M. tuberculosis growth and spread [1]. A Th1 re-
sponse, and in particular interferon γ (IFNγ) production,
are essential for the activation of macrophages and the* Correspondence: danielle.carpenter@nottingham.ac.uk
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stated.control of infection [2,3]. Tumour necrosis factor (TNF)-α
and IFN-γ activate the production of pro-inflammatory
cytokines, including TNF-α and in particular macrophage
inflammatory protein (MIP)-1α and MIP-1β, which have
been shown to play a role in recruitment and activation of
macrophages and leucocytes at the sites of infection [4,5].
Previous studies have demonstrated the central role of
MIP-1α in the host’s protective immune response to
other intracellular pathogens; MIP-1α is essential for the
clearance of Listeria monocytogenes infection [6], and to
activate macrophages critical for the eradication of
Leishmania [7]. As MIP-1α functions as a chemoattract-
ant for monocytes, macrophages and lymphocytes it may
play a crucial role in TB pathogenesis. MIP-1α has been
detected in the lungs of mice in response to infection with
TB [8], and increased MIP-1α mRNA expression has been
observed in humans infected with TB [9,10]. MIP-1α
mRNA expression and protein production has been shown
to be upregulated by M. tuberculosis stimulation, and se-
cretion of MIP-1α was detected during the generation ofral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
Table 1 Number of genotyped cases and control for each
population
Population Cases Controls Total
Adult Paediatric Adult Paediatric
Peruvian 621 0 511 0 1132
!Xhosa 0 141 341 123 605
Coloured 0 56 152 13 221
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observed to be higher in HIV patients with pulmonary TB
than in controls (patients with HIV but without TB infec-
tion) [12].
MIP-1α is a small, low molecular weight, β-chemokine
and acts as a pro-inflammatory cytokine [13,14]. MIP-1α
is encoded by the genes CCL3 and the copy number vari-
able paralogous gene CCL3L1, located on chromosome
17, which exhibit a high degree (96%) of nucleotide and
protein similarity. More specifically, CCL3 and CCL3L1
encode MIP-1α isoforms LD78α and LD78β respectively,
with the isoform LD78β being 2-fold more efficient at
chemoattracting human lymphocytes than the LD78α
isoform [15].
MIP-1α is the natural ligand for the C-C chemokine
receptor type 5 (CCR5), present on many immune cells
including macrophages, T-cells and dendritic cells, and
functions in the movement of leucocytes to sites of in-
fection. During M. tuberculosis infection expression of
CCR5 has been shown to be upregulated [16-18], and this
receptor preferentially used [19], suggesting a major role
in the trafficking of leukocytes during TB infection. CCR5
is encoded by the gene CCR5 on chromosome 3, and
polymorphisms within CCR5 have been identified which
alter the response of CCR5 to chemokines including
alterations to the ligand binding properties of CCR5
[20-22] and a promoter polymorphism in CCR5 -2459A >
G (rs1799987), shown to influence expression levels of
CCR5 [23]. Recently a CCR5 promoter haplotype, CCR5-
HDD, known to increase susceptibility to HIV-1, has
also been associated with TB infection [24].
The aim of this study is to investigate the influence of
genetic variation in the genes coding for MIP-1α and
CCR5 in susceptibility to clinically active TB infection in
three different populations, Peruvian, !Xhosa and South
African Coloured. Copy number variation of CCL3L1 is
investigated, and the functional promoter polymorphism
in CCR5 -2459A > G (rs1799987) is examined.
Methods
Study population
This study analyses samples from three populations, a
Peruvian population from Lima (n = 1132), and two pop-
ulations from the Western Cape region of South Africa;
an isolated !Xhosa population (n = 605) and a South
African Coloured population of mixed ancestry (n = 221)
(see Table 1). All gDNA was isolated from whole blood.
The population samples from Peru were collected be-
tween 1999 and 2002 from the north of Lima City, with
approval of the joint ethics committee of Universidad
Peruana Cayetano Heredia and with informed consent
and have previously been described [25,26]. In brief the
samples consist of adult patients with clinical diagnosis
of pulmonary (n = 498), pleural (n = 79), miliary (n = 35)or other extra-pulmonary (n = 9) forms of TB. There
were 511 age-matched healthy adult control individuals
(age range 32.56 ±9.39 years) from the same geograph-
ical area of Lima as the cases and with a similar socioeco-
nomic background and no past history of TB. Patients
were not enrolled in the study if presenting with HIV in-
fection, diabetes mellitus or other disease increasing the
risk of developing TB.
The two South African population samples, !Xhosa
and Coloureds, consisted of paediatric and adult samples
and were collected with the approval of the ethics com-
mittees of University of Cape Town, South Africa and
St Mary’s Hospital, London, UK and with informed con-
sent. The paediatric samples (n = 333) included both
!Xhosa and Coloured samples and both TB cases and con-
trols (Table 1) and were all from crowded townships in
Cape Town and have previously been described [27]. All
the paediatric samples were tested for HIV and found to
be negative. Some, but not all of the paediatric cases were
clinically diagnosed with pulmonary (!Xhosa n = 55;
Coloured n = 24) and extra-pulmonary TB (!Xhosa n = 82;
Coloured n = 31). The paediatric controls were all age-
matched and from the same neighbourhood as the cases
The adult !Xhosa and Coloured samples (n = 493) con-
sisted entirely of control samples and were more stringent
controls as there was no history of previous TB disease
during childhood and all had a positive Mantoux test to
confirm exposure to M. tuberculosis.
Copy number measurement
CCL3L1 copy number was measured from genomic DNA
using the paralogue ratio test (PRT) previously described
by Carpenter et al. [28,29], modified from the method of
Walker et al. [30]. Briefly, the PRT method is a PCR based
assay using a single pair of primers to simultaneously
amplify two specific products in a single reaction, one
from a single-copy reference locus and the other from a
copy variable test locus of interest [31]. The copy number
of the test locus is then estimated from the ratio of test to
reference PCR products. The Peruvian samples were mea-
sured using a single tube triplex assay [29], whereas the
!Xhosa and Coloured samples were measured using a
three tube triplex assay with two microsatellite assays [28].
For each sample the products from the PCR reactions
were mixed with 10μl HiDi formamide with ROX-500
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lysis was carried out by electrophoresis on an ABI3100
36 cm capillary using POP-4 polymer with an injection
time of 30s at 2kV.
GeneMapper software (Applied Biosystems) was used
to extract the peak areas of the PRT products and the ratio
of test to reference amplicons was calculated for each sam-
ple independently. Copy number values were calculated by
calibrating the ratios; for the Peruvian samples calibration
used European ECACC HRC-1 (www.hpacultures.org.uk)
samples [C0075 with a copy number (CN) = 1; C0150 with
CN= 2; C0007 with CN= 3; and C0877 with CN = 4],
which were included in every experiment in duplicate, and
calibrating the !Xhosa and Coloured samples used 5
Yoruba HapMap samples (www.coriell.org) [copy number
(CN) =2, NA19159; CN = 3, NA18870; CN= 4, NA19092;
CN = 5, NA19171; and CN = 6, NA18503], which were
included in every experiment in triplicate. Unrounded
and calibrated copy numbers were compared and an aver-
age copy number value calculated. For the !Xhosa and
Coloured samples the average copy number was then com-
pared with microsatellite data to ascertain integer copy
number (see Additional file 1).
CCR5 genotyping
The CCR5 gene contains a number of polymorphisms,
some of which have previously shown associations with
susceptibility to HIV-1 infection [23,32-34]. In this study
we chose to investigate a CCR5 promoter polymorph-
ism, -2459A > G, that has been shown to influence ex-
pression of the CCR5 receptor, such that the −2459*A
allele tends to have increased promoter activity [23,35].
Furthermore in vivo association studies provide support
for this as it has been shown that −2459*AA HIV-1 infec-
tion individuals progress more rapidly than those with
a −2459*GG genotype [23].
CCR5 SNP (rs1799987) -2459A > G genotyping was
performed by PCR-RFLP using a previously designed
method [23]. Briefly the primers (forward 5′–CCC GTG
AGC CCA TAG TTA AAA CTC-3′ and reverse 5′-TCA
CAG GGC TTT TCA ACA GTA AGG-3′) generate an
amplicon of 286bp in length. In the −2459*G allele this
is cleaved by Bsp1286I to produce 3 fragments of 127bp
and 149bp, and 10bp. The second cleavage fails to occur
in the presence of the −2459*A allele and so only a band
of 276bp is observed, as well as the small 10bp band on
a 2% (w/v) agarose gel.
Statistical analysis
The difference in mean CCL3L1/CCL4L1 copy number be-
tween the three population samples was initially assessed
using an ANOVA. The distribution of CCL3L1/CCL4L1
copy number in all populations closely follows a normal
distribution, and therefore a two-tailed t- test was used toassess differences in the means between cases and controls
and between pairs of populations. CCR5 allele frequencies
were calculated manually from genotype frequencies from
the different populations using the control samples only.
CCR5 genotype distributions were compared between pop-
ulations and between patients and controls using a χ2 test
in SPSS. To investigate the influence of CCR5 genotype on
disease, adjusting for copy number variation, logistic re-
gression was performed in SPSS with CCL3L1 copy num-
ber and CCR5 genotype as a continuous covariates.
Results
Copy number measurements
The distribution of integer copy number for the Peruvian
population samples is shown in Additional file 1: Table S1
and suggests a range of 0–6 copies, with a mean of 3. The
concordance between PRT measurements is strong, with
96% of samples having all measurements concordant
within 0.75 of the assigned integer, and low probability of
error as discussed in detail in the Additional file 1.
The distributions of integer copy numbers for the !Xhosa
and Coloured samples are shown in Additional file 1:
Tables S2 and Table S3 suggesting the !Xhosa samples to
have a broad range and mean copy number of 4, whereas
the Coloured samples have a mean of 3. In general the
concordance between the nine PRT measurements is good
and the microsatellite data are in agreement with the con-
sensus integer in 94% of all South African samples. The
distribution of unrounded copy number, probability of
error and accuracy of the copy number genotyping are all
examined in detail in the Additional file 1.
The three populations have different distributions of
CCL3L1/CCL4L1 copy numbers, with the !Xhosa popu-
lation having a significantly different mean to both the
Peruvian (p < 0.0001) and Coloured (p < 0.0001) popula-
tions (Figure 1).
Analysis of association between CCL3L1/CCL4L1 copy
number and TB
For the Peruvian population no significant differences were
observed between the control samples (n = 511), with all
clinically active TB cases (n = 621) (p = 0.222) (Figure 2a)
and then with the subtypes of cases separately; pulmonary
(n = 498) (p = 0.279), pleural (n = 79) (p = 0.674), miliary
(n = 35) (p = 0.849) or other extrapulmonary (n = 9) (p = n/s)
forms of TB. To see whether copy number influences the
severity of TB comparison between the pulmonary sam-
ples with the pleural, miliary and other extra-pulmonary
samples combined was performed, and no significant dif-
ference was observed (p = 0.335).
For the !Xhosa population no significant difference in the
mean copy number between the paediatric cases (n = 141),
and both the paediatric controls (n = 123) (p = 0.841) and
the adult controls (n = 341) (p = 0.199) (Figure 2b) was
Figure 1 Copy number distribution within the different populations. The distribution of copy number values in the different populations
with the Peruvian population in black, !Xhosa population in white and Coloured population in grey.
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verity differences between pulmonary (n = 55) and extra-
pulmonary (n = 82) TB samples were performed but no
significant difference was observed (p = 0.939).
For the smaller Coloured population no significant differ-
ence in the means between the paediatric cases (n = 53), and
both the paediatric controls (n = 13) (p = 0.06) and the adult
controls (n = 152) (p = 0.591) (Figure 2c) was observed. To
address whether copy number influences severity of TB
in the Coloured population differences in the mean copy
number between pulmonary (n = 24) and extra-pulmonaryFigure 2 Copy number distributions between cases and controls with
(n = 610) and control samples (n = 513), (b) !Xhosa paediatric cases (n = 141
cases (n = 53) and adult control samples (n = 152). Cases are shown in blac
copy number between the cases and controls for any dataset.(n = 31) TB samples were performed but no significant
difference were observed (p = 0.981).
Analysis of association between CCR5 genotypes and TB
The allele frequencies of the CCR5 SNP (rs1799987) dif-
fer between the three populations, and significant differ-
ences (p < 0.0001) were observed between the frequency
in Peru and the frequency of the two South African popula-
tions (*A; Peru f = 0.67, !Xhosa f = 0.38, Coloured f = 0.48)
(see Figure 3). Case–control analysis with CCR5 genotype
was performed for all three populations between all thein the different populations. Histogram of the (a) Peruvian TB cases
) and adult control samples (n = 341) and (c) Coloured paediatric
k and controls in white. There are no significant differences in mean
Figure 3 Distribution of CCR5 genotypes in the different populations. The distribution of CCR5 genotypes in the different populations, with
the Peruvian population in black, !Xhosa population in white and Coloured population in grey.
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bined for the !Xhosa and Coloured populations) and also
between pulmonary TB and other extrapulmonary TB
forms. No significant association was observed between
CCR5 genotypes with any of the clinically active TB pheno-
types for any population (see Tables 2, 3 and 4).
Combined analysis of CCL3L1 copy number variation and
CCR5 genotype on disease
To investigate the influence of both polymorphisms sim-
ultaneously on disease we investigated the distribution
of CCR5 genotypes with CCL3L1 copy number and per-
formed a logistic regression. There was no clear evidence
for an association of combined CCR5 genotype and copy
number with the Peruvian population between all clinic-
ally active TB cases and controls (see Additional file 2:
Figure S4), and also between control samples and differ-
ent TB subtypes. For the !Xhosa population there is
some suggestion with the logistic regression for an effect
of CCL3L1 copy number when combined with CCR5Table 2 The distributions of CCR5 genotypes in cases and con
Genotypes Controls All cases Pulmona
AA 218 (44%) 275 (46%) 218 (45%)
AG 220 (44%) 265 (44%) 218 (45%)
GG 62 (12%) 61 (10%) 50 (10%)genotype (p = 0.042). The histogram (see Additional file 3:
Figure S5) showing the distribution of the raw data how-
ever does not obviously support this inference and there-
fore suggests potentially a type I error (p = 0.126 after
Bonferroni correction). There was some suggestion with
the Coloured population for an increased proportion of
TB cases (14%) presenting with an *AA genotype on a
2-copy background (see Additional file 4: Figure S6), but
this is not significant by logistic regression analysis. There
was also no evidence for an association of combined
CCR5 genotype and copy number between pulmonary
Coloured cases and extra-pulmonary Coloured cases.
Discussion
Detailed analysis of the raw copy number data generated
from the PRT methodology shows the copy number geno-
typing in the Peruvian population to have a high degree of
accuracy in integer copy number prediction, and that the
high level of accuracy is consistent with other datasets
[28,30]. Whilst the raw copy number data generated fortrols for the Peruvian samples
ry Pleural Military Extra pulmonary
36 (47%) 16 (55%) 5 (56%)
33 (43%) 11 (38%) 3 (33%)
8 (10%) 2 (7%) 1 (11%)
Table 3 The distributions of CCR5 genotypes in cases and
controls for the !Xhosa samples
Genotypes Cases Paediatric
controls
Adult
controls
All controls
AA 15 (10%) 22 (18%) 52 (14%) 74 (15%)
AG 79 (53%) 47 (40%) 169 (47%) 216 (45%)
GG 56 (37%) 50 (42%) 144 (39%) 194 (40%)
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has previously been described for African samples [29],
the PRT data and the microsatellite data are consistent in
copy number estimation and integer copy number can be
assigned with confidence.
This study is the first to investigate susceptibility to
clinically active TB in African and Peruvian populations
with CCL3L1/CCL4L1 copy number variation. As there
is good evidence that strains of M. tuberculosis differ
geographically, so it is possible that the key factors in
the immune response will differ geographically also [36].
There was, thus, the firm potential in this study, with
three diverse populations, to identify associations in
one population but not any of the other. However, sur-
prisingly the association studies of CCL3L1/CCL4L1 copy
number provide no evidence for an association of copy
number with clinically active TB in all three populations.
A previous study (n = 298) found evidence individuals
with CCL3L1 copy numbers greater than the average
(CN = 2) were associated with increased susceptibility
to active TB in a Colombian population [24]. However
our study could not replicate this observation in Peruvian
samples despite the greater sample size. It has previ-
ously been reported that higher copy numbers of CCL3L1/
CCL4L1 are associated with increased MIP-1α levels
and enhanced chemotactic activity [37], which suggests
an increased recruitment of immune mediators and po-
tential immunopathology in TB in individuals with
higher copy numbers. A recent study by our lab, investi-
gating the consequence of copy number variation at
CCL3L1 did not find significant evidence for an associ-
ation between increased MIP-1α levels and CCL3L1 copy
number, and actually suggested that variance in expression
of the non-copy variable gene CCL3 is of more biological
consequence [38].Table 4 The distributions of CCR5 genotypes in cases and
controls for the coloured samples
Genotypes Cases Paediatric
controls
Adult
controls
All controls
AA 17 (29%) 1 (10%) 45 (30%) 46 (28%)
AG 23 (40%) 5 (45%) 59 (40%) 64 (40%)
GG 18 (31%) 5 (45%) 46 (30%) 51 (32%)There was no evidence provided by this study for an as-
sociation of TB susceptibility with the functional CCR5
polymorphism (rs1799987). There is strong linkage dis-
equilibrium across the CCR5 promoter and recently CCR5
promoter haplotypes have been studied in relation to TB
susceptibility [24]. The polymorphism studied here was in-
cluded in that analysis along with 6 other polymorphisms,
and a CCR5 promoter haplotype containing the −2459*G
allele was shown to be significantly associated with TB, in-
dependent of age and sex and CCL3L1 copy number.
Interestingly there was a marked difference in CCR5
allele frequencies between the different populations,
such that in Peru the high expression allele predomi-
nates, whereas in the !Xhosa population it is the low ex-
pression allele that is in the majority. This has implications
in the immune response to other infectious disease,
including HIV infection which uses CCR5 as a co-
receptor for cell entry [39,40]. It is also possible that as the
CCR5 low expression allele predominates in Africa this
may play a role, albeit minor, in the maintenance of higher
CCL3L1/CCL4L1 copy numbers in African samples to
compensate.
The lack of association observed with the CCR5 poly-
morphism may be due to the fact that CCR5 function
can be compensated for by other receptors with overlap-
ping specificities. MIP-1α has been shown to also func-
tionally interact with receptors CCR1 and CCR3, both of
which are present on numerous immune cells. Mice that
lack CCR5 can still induce a Th1 response, control infection
and recruit immune cells to form a granuloma when in-
fected with M. tuberculosis [41], and can control infection
with L. donovani, another macrophage pathogen [42]. Fur-
thermore, individuals who are homozygous for CCR5Δ32,
thus having no functioning CCR5 receptor, appear to be
immunologically normal [21].
The three populations analysed here provided no evi-
dence for any associations with clinically active TB sus-
ceptibility when investigating variations in CCR5 and
CCL3L1 copy number together. The correlation of vari-
ants in the chemokine-chemokine receptor pair with TB
susceptibility may have been anticipated from func-
tional analyses, but our data does not support this. A
recent observation identified that haplotypes in CCR5
associated with increased expression of CCR5 are as-
sociated with TB susceptibility in individuals with 2 cop-
ies or more of CCL3L1 [24]. Our understanding of the
precise role of cytokines in TB infection remains limited
(reviewed in [43]) and there is much compensation and
overlap of roles due to the complexity of the system. To
conclude, whilst functional studies have provided evidence
that both MIP-1α and CCR5 may play a role in TB sus-
ceptibility, this study of genetic variation in CCL3L1 and
CCR5 does not provide additional evidence to support
these roles.
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Additional file 1: A detailed description of how integer copy
number was assigned. Figure S1 Distribution of average calibrated copy
number values for the 1132 genotyped Peruvian samples. Figure S2
Distribution of (a) average calibrated copy number values and (b) with
additional microsatellite data included (represented by a different colour
for each integer) for the 493 genotyped South African adult samples,
comprising 341 !Xhosa samples and 152 Coloured samples. Figure S3
Distribution of (a) average calibrated copy number values and (b) with
additional microsatellite data included (represented by a different colour
for each integer) for the 343 genotyped South African paediatric samples
comprising 264 !Xhosa samples, 69 Coloured samples and 10 samples of
unknown ethnicity.
Additional file 2: Figure S4. Histogram of all the Peruvian case and
control data stratified by both copy number and CCR5 genotype. The
histogram shows no significant difference in the distribution of CCR5
genotype with CCL3L1/CCL4L1 copy number between the cases and controls.
Additional file 3: Figure S5. Histogram of all the !Xhosa case and control
data stratified by both copy number and CCR5 genotype. The histogram
shows no significant difference in the distribution of CCR5 genotype with
CCL3L1/CCL4L1 copy number between the cases and controls.
Additional file 4: Figure S6. Histogram of all the Coloured case and
control data stratified by both copy number and CCR5 genotype. The
histogram shows some suggestion of a distortion in the distribution of
AA genotype on a 2-copy background in the cases.Competing interests
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